Therapeutic perspectives for melatonin agonists and antagonists

Journal of Neuroendocrinology

Volumn 15, Issue 4, 2003, Pages 442-448

  Delagrange, Philippe ^a   Atkinson, J ^b   Boutin, J A ^a   Casteilla, L ^c   Lesieur, D ^e   Misslin, R ^c   Pellissier, S ^d   Penicaud L ^c   Renard, P ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c CNRS   (France)

^d UNIVERSITÉ DE SAVOIE   (France)

^e Campus Scientifique Savoie Technolac ^*

Author keywords

Melatonin; Melatonin receptors; Models; Pathology

Indexed keywords

ANXIOLYTIC AGENT; CHOLECYSTOKININ; FLUOXETINE; HORMONE ANTAGONIST; HYDROXYETHYLCELLULOSE; LEPTIN; LEPTIN RECEPTOR; LIGAND; MELATONIN; MELATONIN RECEPTOR; MESSENGER RNA; N [2 (1 NAPHTHYL)ETHYL]CYCLOBUTANECARBOXAMIDE; NEUROHORMONE; RECEPTOR SUBTYPE; S 20304; S 22153; UNCLASSIFIED DRUG;

ADAPTATION; ADIPOCYTE; ARTERIOLE; ARTERY CONSTRICTION; AUTOREGULATION; BINDING SITE; BIODIVERSITY; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CIRCADIAN RHYTHM; DARKNESS; DEPRESSION; DIGESTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG HALF LIFE; HORMONE SYNTHESIS; HUMAN; IN VIVO STUDY; INTESTINE FUNCTION; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; LIGHT DARK CYCLE; MENTAL STRESS; METABOLIC REGULATION; MOLECULAR EVOLUTION; MOTOR PERFORMANCE; MULTIINFARCT DEMENTIA; NEOPHOBIA; NONHUMAN; OBESITY; PERFUSION; PINEAL BODY; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; RISK ASSESSMENT; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; BODY WEIGHT; BRAIN; CEREBROVASCULAR CIRCULATION; CHRONOBIOLOGY DISORDERS; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GASTROINTESTINAL MOTILITY; MELATONIN; MICE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, MELATONIN;

EID: 0345726360     PISSN: 09538194     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2826.2003.01016.x     Document Type: Review

References (39)

1. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-180.
2. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13: 1177-1185.
3. 1b melatonin receptor. Proc Natl Acad Sci USA 1995; 92: 8734-8738.
4. Dubocovich ML, Cardinali DP, Delagrange P, Krause DN, Strosberg AD, Sugden D, Yocca FD. The IUPHAR Compendium of Receptor Characterization and Classification. London: IUPHAR Media; 2000: 271-277.
5. Mazzucchelli C, Pannacci M, Nonno R, Lucini V, Fraschini F, Stankov BM. The melatonin receptor in the human brain: cloning experiments and distribution studies. Mol Brain Res 1996; 39: 117-126.
6. 1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport 1996; 8: 109-112.
7. Al-Ghoul WM, Herman MD, Dubocovich ML. Melatonin receptor subtype expression in human cerebellum. Neuroreport 1998; 9: 4063-4068.
8. Morgan PJ, Barrett P, Howell HE, Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int 1994; 24: 101-146.
9. 125I]iodomelatonin binding sites correlated with expression of Mel1a and Mel1b receptor genes. J Endocrinol 1998; 156: 261-267.
10. 1a subtype localized primarily to the basolateral membrane of the proximal tubule. FASEB J 1997; 11: 93-100.
11. Brydon L, Petit L, Delagrange P, Strosberg AD, Jockers R. Functional expression of mt2 (mel1b) melatonin receptors in human paz6 adipocytes. Endocrinology 2001; 142: 4264-4271.
12. 3 as the quinone reductase 2. J Biol Chem 2000; 257: 31311-31317.
13. Arendt J, Skene DJ, Middleton B, Lowley SW, Deacon S. Efficacy of melatonin in jet-lag, shift work and blindness. J Biol Rhythms 1997; 12: 604-617.
14. Krauchi K, Cajochen C, Mori D, Graw P, Wirz-Justice A. Early evening melatonin and S 20098 advance circadian phase and nocturnal regulation of care body temperature. Am J Physiol 1997; 272: R1178-R1188.
15. Delagrange P, Guardiola-Lemaître B. Melatonin, its receptors and relationships with biological rhythms disorders. Clin Neuropharmacol 1997; 20: 482-510.
16. Kopp C, Vogel E, Rettori MC, Delagrange P, Guardiola-Lemaitre B, Misslin R. Effects of melatonin on neophobic responses in different strains in mice. Pharm Biochem Behav 1999; 63: 521-526.
17. Weibel L, Rettori MC, Lesieur D, Delagrange P, Renard P, Van Reeth O. A single oral dose of S 22153, a melatonin antagonist, blocks the phase advancing effects of melatonin in C3H mice. Brain Res 1999; 829: 160-166.
18. Kopp C, Vogel E, Rettori MC, Delagrange P, Renard P, Lesieur D, Misslin R. Antagonistic effects of S 22153, a new mt1 and MT2 receptor ligand, on the neophobia-reducing properties of melatonin in Balb/c mice. Pharm Biochem Behav 1999; 64: 131-136.
19. Kopp C, Vogel E, Rettori MC, Delagrange P, Misslin R. Anxiolytic-like properties of melatonin receptor agonists in mice: involvement of mt1 and/or MT2 receptors in the regulation of emotional responsiveness. Neuropharmacology 2000; 39: 1865-1871.
20. Kopp C, Vogel E, Rettori MC, Delagrange P, Misslin R. Effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav Pharmacol 1999; 10: 73-83.
21. Viswanathan M, Scalbert E, Delagrange P, Guarchola-Lemaitre B, Saavedra JM. Melatonin receptors mediate contraction of a rat cerebral artery. Neuroreport 1998; 8: 3847-3849.
22. Geary GG, Krause DN, Duckles SP. Melatonin directly constricts rat cerebral arteries through modulation of potassium channels. Am J Physiol 1997; 273: H1530-H1536.
23. Régrigny O, Delagrange P, Scalbert E, Lartaud-Idjouadiene I, Atkinson J, Chillon JM. Effects of melatonin on rat pial arteriolar diameter in vivo. Br J Pharmacol 1999; 127: 1666-1670.
24. Régrigny O, Delagrange P, Scalbert E, Atkinson J. Lartaud-Idjouadiene. Melatonin improves cerebral circulation security margin in rats. Am J Physiol 1998; 275: H139-H144.
25. Régrigny O, Dupuis F, Atkinson J, Liminana P, Scalbert E, Delagrange P, Chillon JM. Cerebral arteriolar structure and function in pinealectomized rats. Am J Physiol 2001; 281: H1476-H1480.
26. Régrigny O, Atkinson J, Liminana P, Scalbert E, Delagrange P, Chillon JM. Effects of melatonin treatment on cerebral arteriolar structure and mechanics and cerebral autoregulation in old rats. Fundam Clin Pharmacol 2001; 15: 144.
27. Atkinson J. Cerebrovascular structure and dementia: new drug targets. TIPS 2001; 22: 630-635.
28. Bartness TJ, Wade GN. Photoperiodic control of seasonal body weight cycles in hamsters. Neurosci Biobehav Rev 1985; 9: 599-612.
29. Le Gouic S, Delagrange P, Atgie C, Nibbelink M, Hanoun N, Casteilla L, Renard P, Lesieur D, Guardiola-Lemaitre B, Ambid L. Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the garden dormouse. Int J Obesity 1996; 20: 661-667.
30. 2 receptors by CRE-luciferase reporter assay. Eur J Pharmacol 2000; 390: 15-24.
31. Depreux P, Lesieur D, Ait Mansour H, Morgan P, Howell HE, Renard P, Caignard DH, Pfeiffer B, Delagrange P, Guardiola B, Yous S, Demarque A, Adam G, Andrieux J. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J Med Chem 1994; 37: 3231-3239.
32. Le Gouic S, Atgié C, Viguerie-Bascands N, Hanoun N, Larrouy D, Ambid L, Raimbault S, Ricquier D, Delagrange P, Guardiola-Lemaître B, Pénicaud L, Casteilla L. Characterization of a melatonin binding site in Siberian hamster brown adipose tissue. Eur J Pharmacol 1997; 339: 271-278.
33. Canpolat S, Sandal S, Yilmaz B, Yasar A, Kutlu S, Baydas G, Kelestimur H. Effects of pinealectomy and exogenous melatonin on serum leptin levels in male rat. Eur J Pharmacol 2001; 428: 145-148.
34. Drijfhout WJ, Grol CJ, Westerink BHC. Microdialysis of melatonin in the rat pineal gland: methodology and pharmacological applications. J Neurochem 1993; 61: 936-942.
35. Pontoire CH, Bernard M, Silvain Ch, Collin JP, Voisin P. Characterization of melatonin binding sites in chicken and human intestines. Eur J Pharmacol 1993; 247: 111-118.
36. Merle A, Delagrange P, Renard P, Lesieur D, Cuber JC, Roche M, Pellissier S. Effect of melatonin on motility pattern of small intestine in rats and its inhibition by melatonin receptor antagonist S 22153. J Pineal Res 2000; 29: 116-124.
37. Merle A, Faucheron JL, Delagrange P, Renard P, Roche M, Pellissier S. Nycthemeral variations of cholecystokinin action on intestinal motility in rats effects of melatonin and S 20928, a melatonin receptor antagonist. Neuropeptides 2000; 34: 385-391.
38. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Speizer FE, Hennekens CH. Prospective study of shift work and risk of coronary heart disease in women. Circulation 1995; 92: 3178-3182.
39. Karlsson B, Knutsson A, Lindahl B. Is there an assocation between shift work and having a metabolic syndrome? Results from a population based study of 27,485 people. Occup Environ Med 2001; 58: 747-752.